BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients,Tumori Journal

当前位置： X-MOL 学术 › Tumori J. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients
Tumori Journal ( IF 1.9 ) Pub Date : 2022-12-06 , DOI: 10.1177/03008916221141483
Sebastiano Buti _{1,

2} , Francesca Trentini ₁ , Pierangela Sepe ₃ , Melanie Claps ₃ , Luca Isella ₁ , Elena Verzoni ₃ , Giuseppe Procopio ₄

Affiliation

Background:The BONSAI phase II trial recently demonstrated the activity of cabozantinib in metastatic collecting duct patients. The outcomes of patients in this setting treated with immunotherapy a...

中文翻译：